Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19
Sponsor: ImmunityBio, Inc.
Terminated
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
Other terminated trials from ImmunityBio, Inc.
- Non Small Cell Lung Cancer · Oct 2025
- COVID-19 · Phase PHASE1/PHASE2 · Mar 2024
- Triple Negative Breast Cancer · Phase PHASE1/PHASE2 · Jan 2024
- COVID-19 · Phase PHASE2/PHASE3 · Jul 2023
- Covid19 · Phase PHASE1 · Jan 2023
More terminations from ImmunityBio, Inc.
Listed as NCT04385849, this PHASE1 trial focuses on COVID-19 and remains terminated or withdrawn. Sponsored by ImmunityBio, Inc., it has been updated 9 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE1
Status: Unknown → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Sep 2021 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 4 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ImmunityBio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .